Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies다양한 질병 조절 요법을 받는 다발성 경화증 환자의 COVID-19 감염 및 중증 질환 위험Article Published on 2022-04-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95% CI Analysis anti-CD20 association CDC center clinical symptom Comprehensive conducted COVID-19 COVID-19 cases COVID-19 infection death deaths determine disease disease severity disease-modifying therapy. Evidence fumarate Hospitalization increased risk individual Infection Laboratory testing MOST Multiple multiple sclerosis observé Patient patient population patients treated patients with SARS-CoV-2 predictor receptor risk rituximab SARS-CoV-2 IgG SARS-CoV-2 infected individual SARS-COV-2 infection SARS-CoV-2 PCR severe COVID-19 severe disease severe SARS-CoV-2 severity significantly statistical significance therapy was determined was used [DOI] 10.1016/j.msard.2022.103735 PMC 바로가기 [Article Type] Article
Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 casesObservational Study Published on 2022-04-012022-10-04 Journal: Infectious diseases (London, England) [Category] Coronavirus, COVID19(2023년), SARS, 임상, [키워드] acute respiratory syndrome antibodies case sery cause CCP clinically convalescent convalescent plasma convalescent plasma treatment coronavirus COVID-19 COVID-19 infection decrease defined died Efficacy heterogeneous group Hospitalized hospitalized patient Immunocompromised patients immunosuppressed patient Immunosuppression In-hospital lymphoma pandemic Patient patients patients hospitalized PCR performed plasma Prospective randomized trial retrospective rituximab SARS-CoV-2 severe immunosuppression Severe infection standard treatment Study design symptom duration treated Treatment Treatment outcome Viremia Virological [DOI] 10.1080/23744235.2021.2013528 PMC 바로가기 [Article Type] Observational Study
[Retrospective observational study of the persistence of SARS-CoV-2 infection in patients previously treated with rituximab][이전에 리툭시맙 치료를 받은 환자에서 SARS-CoV-2 감염 지속성에 대한 후향적 관찰 연구]Observational Study Published on 2022-04-012022-09-12 Journal: Revista española de quimioterapia : publicación [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] age analyzed association B-cell function blood pressure carried COVID-19 CRP cumulative Demographic variables Descriptive analysis disease dose English Evolution Follow-up high risk Immunity Immunosuppression increased risk Infection Lung disease material media median men Mortality mortality rate obesity observé Pandemia pandemic Patient patients PCR persistence Prevalence progression risk factor rituximab SARS-CoV-2 SARS-COV-2 infection SARS-CoV2 screened severe COVID-19 Spanish statistically significant difference Thromboembolic events treated Treatment uninfected variable ventilatory support viral infection virus [DOI] 10.37201/req/122.2021 PMC 바로가기 [Article Type] Observational Study
Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitisObservational Study Published on 2022-04-012023-07-07 Journal: Annals of the rheumatic diseases [Category] COVID19(2023년), [키워드] Autoimmune diseases COVID-19 rituximab vaccination [DOI] 10.1136/annrheumdis-2021-221747 [Article Type] Observational Study
Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphomaarticle Published on 2022-03-042024-09-02 Journal: Annals of Hematology [Category] 대상포진, [키워드] Bendamustine hydrochloride diffuse Large B cell lymphoma recurrence rituximab salvage therapy [DOI] 10.1007/s00277-022-04801-2 PMC 바로가기 [Article Type] article
Protracted or recurrent COVID-19 associated cytokine storm in a patient with chronic lymphocytic leukemia receiving rituximab-based chemotherapy리툭시맙 기반 화학요법을 받고 있는 만성 림프구성 백혈병 환자에서 장기간 또는 재발하는 COVID-19 관련 사이토카인 폭풍Case Reports Published on 2022-03-012022-09-12 Journal: Clinical immunology (Orlando, Fla.) [Category] MERS, 진단, [키워드] addition Administered Anakinra Chemotherapy Corticosteroids Course COVID-19 Cyclophosphamide Cytokine storm Cytokine storm (hyperinflammatory syndrome) diagnosed diagnosed with COVID-19 died discharge fatigue Fever hospital Hospitalization Hyperinflammatory Hypoxemia intravenously laboratory parameter leukemia male Methylprednisolone oxygen saturation Patient Prednisolone progressed receiving regimen resolved Respiratory failure rituximab severe hypoxemia Shortness of breath Significant the patient Tocilizumab Treatment vincristine [DOI] 10.1016/j.clim.2022.108936 PMC 바로가기 [Article Type] Case Reports
Severe COVID pneumonia and undetectable B cells after vaccination in patients previously treated with rituximab: a case seriesCase Reports Published on 2022-03-012023-07-08 Journal: Postgraduate medicine [Category] COVID19(2023년), [키워드] Antibody Response B cells COVID-19 rituxan rituximab vaccination Vaccine [DOI] 10.1080/00325481.2022.2037359 [Article Type] Case Reports
Dynamic of humoral response to SARS-CoV-2 anti-Nucleocapsid and Spike proteins after CoronaVac vaccinationCoronaVac 백신 접종 후 SARS-CoV-2 항-뉴클레오캡시드 및 스파이크 단백질에 대한 체액 반응의 역학Article Published on 2022-03-012022-09-11 Journal: Diagnostic microbiology and infectious disease [Category] MERS, SARS, 진단, 치료법, [키워드] (Abbott Abbott absence administration Anti-S1 antibody Brazil calculate collected CoronaVac Day dynamic dynamic range Euroimmun evaluated first dose Germany HCW HCWs healthcare worker Healthcare workers humoral IgG IgG antibodies IgG antibody immunization immunoassay immunoassays Immunoglobulin Immunoglobulin G Ireland Lubeck N protein nucleocapsid occurred pandemic Protein Public public health quantified rituximab S1 protein SARS-CoV-2 Seroconversion seroconversion rate serum sample serum samples Sligo spike the N protein the S1 protein the vaccine vaccination Vaccine [DOI] 10.1016/j.diagmicrobio.2021.115597 PMC 바로가기 [Article Type] Article
Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy항-CD20 치료 이력이 있는 환자에서 체액성 및 세포성 면역의 궤적과 SARS-CoV-2에 대한 3차 mRNA 백신에 대한 반응Article Published on 2022-03-012022-09-11 Journal: RMD Open [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] Analysis anti-CD20 anti-CD20 therapy anti-CD20 treatment anti-SARS-CoV-2 immune response anti-SARS-CoV-2 immune responses antibody concentration Antibody concentrations cell-mediated immune Cell-mediated immunity cellular immunity CMI comparable Concentration Control covariance COVID-19 decay dose elicited healthy volunteer healthy volunteers humoral humoral and cell-mediated immunity Humoral response humoral responses IgG immune responses Immunity immunogenicity inefficient interferon interferon-γ investigated Linear regression majority mRNA vaccine non-responder non-responders outcome Participants Patient patients registration number Responder responders response reveal rituximab RNA SARS-CoV-2 SARS-CoV-2 vaccine second vaccination systemic vasculitis Therapies therapy Trajectories trajectory Trial Registration Number vaccination Vaccination strategy Vaccine vaccine dose Vasculitis [DOI] 10.1136/rmdopen-2021-002166 PMC 바로가기 [Article Type] Article
Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infectionArticle Published on 2022-03-012023-06-11 Journal: Internal and Emergency Medicine [Category] B형 간염, [키워드] biologics hepatitis B infection precision medicine Rheumatic diseases rituximab [DOI] 10.1007/s11739-021-02836-3